
Global R&D Pipeline
My Favorite
Hot Targets:
ADAM9
Back
Total number of drugs
15
Phase II and later clinical stages
0%
Involving companies
14
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BG-C0979 | BG-C0979 | Antibody drug conjugate (ADC) ADC | Neoplasms | ADAM metallopeptidase domain 9 inhibitors DNA topoisomerase I inhibitors | BeOne Medicines Ltd. | BeOne Medicines Ltd. | Phase 1 | Phase 1 | BG-C0979 | detail > | |||||||||||
| DB-1317 | DB-1317 | Antibody drug conjugate (ADC) ADC | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease Respiratory Diseases Urogenital Diseases | ADAM metallopeptidase domain 9 inhibitors | Duality Biologics (Suzhou) Co., Ltd. | DualityBio Inc. | Phase 1 | Phase 1 | DB-1317 | detail > | |||||||||||
| MGC-028 | MGC-028 | Antibody drug conjugate (ADC) ADC | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease Respiratory Diseases Other Diseases | ADAM metallopeptidase domain 9 inhibitors DNA topoisomerase I inhibitors | MacroGenics, Inc. | MacroGenics, Inc. | Phase 1 | Val-Ala | Exatecan 依喜替康 | 4 | MGC-028 | asparagine 天冬酰胺 | detail > | ||||||||
| Izeltabart | Izeltabart | Monoclonal antibody | ADAM metallopeptidase domain 9 inhibitors | Clinical | Izeltabart | detail > | |||||||||||||||
| Izeltabart Tapatansine | Izeltabart Tapatansine | Antibody drug conjugate (ADC) ADC | ADAM metallopeptidase domain 9 inhibitors Tubulin inhibitors | Clinical | Mal-Ala-Ala | Maytansinoid DM21 DM21 | Izeltabart Tapatansine | IgG1 - kappa | detail > | ||||||||||||
| ADAM9 ADC(Henlius) | ADAM9 ADC(Henlius) | Antibody drug conjugate (ADC) ADC | Neoplasms | ADAM metallopeptidase domain 9 inhibitors | Shanghai Henlius Biotech, Inc. | Shanghai Henlius Biotech, Inc. | Preclinical | Preclinical | ADAM9 ADC(Henlius) | detail > | |||||||||||
| ADAM9 ADC(Hongcheng) | ADAM9 ADC(Hongcheng) | Antibody drug conjugate (ADC) ADC | ADAM metallopeptidase domain 9 inhibitors | Jiangsu Hongcheng Biotechnology Co., Ltd. | Shanghai Huaaotai Biopharmaceutical Co., Ltd. | Preclinical | Preclinical | ADAM9 ADC(Hongcheng) | detail > | ||||||||||||
| Anti-Adam9 Antibody Drug Conjugate(Immunogen) | Anti-Adam9 Antibody Drug Conjugate(Immunogen) | Antibody drug conjugate (ADC) ADC | Neoplasms | ADAM metallopeptidase domain 9 inhibitors Tubulin inhibitors | ImmunoGen, Inc. | ImmunoGen, Inc. | Preclinical | SPDB | Maytansinoid DM4 美登素DM4 | Anti-Adam9 Antibody Drug Conjugate(Immunogen) | lysyl 赖氨酸 | detail > | |||||||||
| Anti-ADAM9 Antibody(Mabwell bioscience) | Anti-ADAM9 Antibody(Mabwell bioscience) | Antibody | Neoplasms | ADAM metallopeptidase domain 9 inhibitors | Mabwell (Shanghai) Bioscience Co., Ltd. | Mabwell (Shanghai) Bioscience Co., Ltd. | Preclinical | Preclinical | Anti-ADAM9 Antibody(Mabwell bioscience) | detail > | |||||||||||
| XYD-8006 | XYD-8006 | Dual payload Antibody drug conjugate (Dual payload ADC) | Neoplasms Digestive System Disorders Respiratory Diseases | ADAM metallopeptidase domain 9 inhibitors Tubulin inhibitors | Kunshan Xinyunda Biotechnology Co., Ltd. | FDC PharmaKunshan Xinyunda Biotechnology Co., Ltd. | Preclinical | Preclinical | MMAE 甲基澳瑞他汀E | XYD-8006 | detail > |
Total 15 data
1
2


